Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease
Diabetic Kidney Disease
About this trial
This is an interventional treatment trial for Diabetic Kidney Disease focused on measuring Diabetic Kidney Disease, Gilead
Eligibility Criteria
Key Inclusion Criteria:
- Adult male or females with prior diagnosis of Diabetic Kidney Disease
- Type 2 diabetes mellitus diagnosis for at least 6 months
- eGFR (MDRD) at screening ≥ 15 mL/min/1.73m^2 to < 60 mL/min/1.73m^2
Urine albumin to creatinine ratio (UACR) as follows:
- Stage/Stratum 3a: eGFR range 45 to < 60 mL/min; UACR ≥ 600 mg/g
- Stage/Stratum 3b: eGFR range 30 to < 45 mL/min; UACR ≥ 300 mg/g
- Stage/Stratum 4: eGFR range 15 to < 30 mL/min; UACR ≥ 150 mg/g
Receiving angiotensin-converting-enzyme inhibitor (ACEi) or angiotensin receptor blockers (ARB) at a minimum dose deemed appropriate for the individual by the investigator and be at a stable dose for the last three months
- Individuals not on ACEi/ARB may be screened if there is documented intolerance to ACE inhibitor and/or ARB
Key Exclusion Criteria:
- Type 1 diabetes mellitus
- HbA1c > 9.5%
- Non-diabetic kidney disease
- UACR > 5000 mg/g on any measurement during screening
- End stage renal disease (ESRD; receiving peritoneal dialysis, hemodialysis, or status post renal transplantation) or anticipated to occur within the treatment period
- Unstable cardiovascular disease
- Pregnant or lactating females
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Sites / Locations
- The University of Alabama at Birmingham (UAB)
- Chase Medcare
- Choice Medicine
- Akdhc Medical Research Services, Llc
- Akdhc Medical Research Services, Llc
- Akdhc Medical Research Services, Llc
- Akdhc Medical Research Services, Llc
- Robert J. Bloomberg, MD
- AKDHC East Office
- Clinical Research Connections, LLC
- North America Research Institute
- California Institute of Renal Research
- California Institute of Renal Research Inc.
- Renal Consultants Medical Group Granada Hills
- Torrance Clinical Research
- IMD Medical Group
- Academic Medical Research Institute
- Kidney Research Center
- Apex Research of Riverside
- San Francisco General Hospital
- Clearview Medical Research, LLC
- American Institute of Research
- Omega Research Consultants
- Creekside Medical Research
- Riverside Clinical Research
- ASA Clinical Research
- FPA Clinical Research
- The Chappel Group LLC
- South Florida Research Institute
- Prestige Clinical Research Center Inc
- International Physicians Research / Nephrology Associates of South Miami
- Tellus Clinical Research, Inc
- Coral Research Clinic Corp
- Suncoast Clinical Research, Inc.
- Discovery Medical Research Group
- Central Florida Internists
- Sunset Point Medical Associates DBA
- Pines Clinical Research Inc.
- Central Florida Internists
- Florida Pulmonary Research Institute
- Rockdale Medical Research Associates
- John H. Stroger Jr. Hospital Of Cook County
- Midwest Endocrinology
- Beacon Medical Group Kidney and Hypertension Center
- West Broadway Clinic
- Hutchinson Clinic, P.A
- Kansas Nephrology Research Institute, LLC
- L-MARC Research Center
- Four Rivers Clinical Research
- Research Nurse Specialists, LLc
- Crescent City Clinical Research Center
- Tulane University
- Internal Medicine Specialists
- Green Clinic LLC
- Northwest Louisiana Nephrology
- Southern Clinical Research
- Johns Hopkins Hospital/University
- A. Kaldun Nossuli MD Research
- Wayne State University
- Apex Medical Research.Com
- Elite Clinical Research
- Troy Internal Medicine, PC
- VA Medical Center
- Mercury Street Medical Group, PLLC, Big Sky Clinical Research, LLC
- Alegent Creighton Health
- Creighton Diabetes Center
- Nephrology and Hypertension Associates of New Jersey
- Albuquerque Clinical Trials
- Nephrology Associates, PC
- Mountain Kidney and Hypertension Associates
- Boice-Willis Clinic
- Carolina Research Center
- Hightop Medical Research Center
- Craig S Thompson MD LLC
- Your Diabetes Endocrine Nutrition Group Inc
- Chris Sholer, MD, PC
- Bend Memorial Clinic
- Southeast Renal Research Institute
- Knoxville Kidney Center
- Arlington Nephrology
- MW Clinical Research Center
- Padre Coast Clinical Research
- Corsicana Medical Research, PLLC
- Texas Tech Univ. Health Sciences Center
- TVC Clinical Research
- Diagnostic Clinic of Houston
- Mercury Clinical Research
- Lakewood Family Practice
- Southwest Clinical Trials
- Southwest Houston Research, Ltd.
- HMRI CCAT Pearland
- Clinical Advancement Center, PLLC
- Briggs Clinical Research, LLC
- San Antonio Kidney Disease Center Physicians Group, P.L.L.C.
- University of Texas Health Science Center at San Antonio
- Val R. Hansen, M.D.
- Fletcher Allen Health Care
- University of Virginia
- University of Wisconsin
- Zablocki VAMC
- BC Diabetes
- Co-Medica Research Network
- Clinical Research Solutions, Inc.
- OTT Healthcare Inc.
- Toronto East General Medical Centre
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Placebo Comparator
Selonsertib 2 mg
Selonsertib 6 mg
Selonsertib 18 mg
Placebo to match selonsertib
Participants will receive selonsertib 2 mg for 48 weeks.
Participants will receive selonsertib 6 mg for 48 weeks.
Participants will receive selonsertib 18 mg for 48 weeks.
Participants will receive placebo to match selonsertib for 48 weeks.